Treatment of lupus patients with the mTOR blockers acetylcysteine [25] or rapamycin [26] provides significant beneficial therapeutic effects that envision potential additional approaches of mTOR blockade (e.g., through calorie restriction [27]) for a possible reduction of the chronic inflammatory state in SLE patients. The gene discussed is MTOR; the disease is systemic lupus erythematosus.